AI Article Synopsis
- Access to direct acting antivirals (DAAs) has significantly lowered hepatitis C virus (HCV) viremia prevalence among people with HIV, dropping from 36% in 2009 to just 2% in 2021.
- Socio-demographic factors like male sex, black race, and older age were linked to HCV viremia in 2009, but these associations were not present by 2021.
- Despite improvements, injection drug use continued to be a consistent risk factor for HCV viremia in both years, highlighting the need for targeted interventions for drug-using populations among people with HIV.
Article Abstract
Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%-46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%-4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10938212 | PMC |
| http://dx.doi.org/10.1093/infdis/jiad433 | DOI Listing |
Publication Analysis
Top Keywords
hcv viremia
16
viremia prevalence
8
associated hcv
8
viremia 2009
8
2009 2021
8
hcv
5
hepatitis treatment
4
treatment people
4
people hiv
4
hiv potential
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!